Phaseline

Companies › AAVantgarde Bio Srl

AAVantgarde Bio Srl: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Other, Ophthalmology; next expected readout Jul 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AAVB-081
AAV gene therapy delivering MYO7A cDNA
MYO7APhase 1Usher Syndrome, Type 1BJul 2029
AAVB-039
adeno-associated virus (AAV) gene therapy delivering ABCA4
ABCA4Phase 1Stargardt DiseaseJul 2032

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06591793AAVB-081Phase 1Usher Syndrome, Type 1BOtherJul 2029
NCT07161544AAVB-039Phase 1Stargardt DiseaseOphthalmologyJul 2032

Targets

MYO7A (1) ABCA4 (1)

Companies with the same targets

VeonGen Therapeutics Ascidian Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.